Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aubrey Roberts

Optometrist Monett, MO Doctor of Optometry

NPI 1679002927 CMS profile 2867246

507 E Cleveland Ave, Monett, MO 65708

Open in the dashboard

General payments

$1,525

50 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aubrey Roberts of Monett, MO is reported in the CMS Open Payments database as having received $1,525 across 50 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 71st percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $141 5
2024 General $402 15
2023 General $476 13
2022 General $96 2
2021 General $163 6
2020 General $144 7
2019 General $102 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aubrey Roberts
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Aubrey Roberts were reported at $141. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Aubrey Roberts Optometrist median Middle half National median
2019 $102 $159 $67–$371 $163
2020 $144 $72 $29–$165 $114
2021 $163 $125 $46–$292 $132
2022 $96 $162 $66–$374 $149
2023 $476 $177 $72–$406 $160
2024 $402 $188 $77–$427 $164
2025 $141 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $674 21 payments
  2. Bausch & Lomb, a division of Bausch Health US, LLC $410 15 payments
  3. CooperVision Inc. $168 4 payments
  4. ABB Con-Cise Optical Group LLC $145 6 payments
  5. Sight Sciences, Inc. $97 2 payments
  6. Optos, Inc. $32 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,493 48 payments
  2. Entertainment $32 2 payments
Products named General payments · program years 2019–2025
  1. INFUSE $771 22 payments
  2. BIOTRUE $162 2 payments
  3. CONTACT LENS $145 6 payments
  4. SPECTACLE LENSES $145 6 payments
  5. ULTRA $142 5 payments
  6. MiSight Contact Lens $98 2 payments
  7. TEARCARE SYSTEM $97 2 payments
  8. BTOD $85 7 payments
  9. BIOTRUE ONE DAY $84 1 payment
  10. MyDay Contact Lens $69 2 payments
  11. Other $160 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

521

Median for Optometry: 120

Drug cost

$10,334

Median for Optometry: $8,864

Branded share of claims

11.1%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 13 $3,173
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 24 $2,096
Latanoprost Generic 246 $2,084
Timolol Maleate Generic 101 $1,003
Prednisolone Acetate Generic 34 $916
Brimonidine Tartrate Generic 51 $449
Dorzolamide Hcl Generic 18 $353
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 21 $210
Doxycycline Hyclate Generic 13 $50

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$30,364

Medicare's payments for the services billed

Medicare patients

282

Average age 75

Services billed

600

184 women, 98 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 40%
Diabetes 24%
Chronic kidney disease 24%
Osteoporosis 15%
Ischemic heart disease 14%
Cancer 14%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

50 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record